Terns Pharmaceuticals (TERN) to Release Earnings on Monday

Key Points

• Terns Pharmaceuticals (NASDAQ:TERN) is set to release its Q2 2025 earnings results on August 4th, with analysts predicting earnings of ($0.29) per share.
• Insider purchases have increased, with CFO Andrew Gengos and CEO Amy L. Burroughs significantly raising their stakes in the company, reflecting confidence in Terns' future.
• Wall Street analysts have mixed views on Terns, with a consensus rating of "Moderate Buy" and a target price of $15.63 despite a recent cut in target price by BMO Capital Markets.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Terns Pharmaceuticals Stock Down 1.6%

Shares of TERN traded down $0.10 on Thursday, reaching $5.82. The stock had a trading volume of 327,187 shares, compared to its average volume of 1,157,331. Terns Pharmaceuticals has a twelve month low of $1.87 and a twelve month high of $11.40. The firm has a market capitalization of $507.88 million, a PE ratio of -5.32 and a beta of -0.11. The firm has a 50-day moving average of $4.31 and a 200 day moving average of $3.74.

Insider Transactions at Terns Pharmaceuticals

In other news, CFO Andrew Gengos acquired 10,000 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average price of $3.93 per share, with a total value of $39,300.00. Following the completion of the purchase, the chief financial officer owned 25,000 shares of the company's stock, valued at approximately $98,250. This represents a 66.67% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amy L. Burroughs acquired 23,314 shares of the stock in a transaction dated Wednesday, June 25th. The stock was acquired at an average cost of $3.87 per share, with a total value of $90,225.18. Following the transaction, the chief executive officer owned 47,083 shares of the company's stock, valued at approximately $182,211.21. This trade represents a 98.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 48,314 shares of company stock worth $186,575. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its stake in Terns Pharmaceuticals by 21.0% during the first quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company's stock worth $1,145,000 after purchasing an additional 71,971 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Terns Pharmaceuticals by 136.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company's stock worth $78,000 after buying an additional 16,363 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Terns Pharmaceuticals in the 1st quarter worth $51,000. 98.26% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TERN. JMP Securities restated a "market outperform" rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a research report on Monday, April 21st. BMO Capital Markets dropped their target price on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $15.63.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.